Breast Cancer | Specialty

Extending AI Therapy Beyond 5 Years Reduces Recurrence in HR-Positive Breast Cancer

June 6th 2016

Women who extended their adjuvant therapy with an aromatase inhibitor to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.

Patient-Driven Research Project Aims to Advance Metastatic Breast Cancer Treatment

June 5th 2016

Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.

Abemaciclib Active Against HR+/HER2- Breast Cancer

June 4th 2016

The CDK4/6 inhibitor abemaciclib induced a response rate of nearly 20% in heavily pretreated patients with refractory, HR-positive, HER2-negative advanced breast cancer, according to findings from the phase II MONARCH 1 trial.

Biosimilar Trastuzumab Matches Herceptin in Efficacy and Safety

June 4th 2016

A biosimilar version of trastuzumab demonstrated equivalent efficacy and safety to the FDA-approved branded drug in a randomized phase III study among patients with HER2-positive metastatic breast cancer.

Despite ASCO Mishap, Data Still Intriguing for Sacituzumab Govitecan in TNBC

June 4th 2016

Sacituzumab govitecan (IMMU-132) had an objective response rate of 33% in pretreated patients with triple-negative breast cancer, according to updated findings from a phase II study reported by Immunomedics, the manufacturer of the antibody-drug conjugate.

Communicating Breast Cancer Genetic Testing Results to Patients

May 31st 2016

Cost Considerations in Breast Cancer Genetic Testing

May 31st 2016

Breast Cancer and Genetic Counseling

May 31st 2016

Next-Generation Sequencing in Breast Cancer

May 31st 2016

Clinical Experience with Multi-Gene Panel Use in Breast Cancer

May 31st 2016

Assessing Breast Cancer Risk: Rationale for Multigene Panel Use

May 31st 2016

Understanding the Options in Multi-Gene Panels

May 31st 2016

Breast Cancer Risks: Guidelines for Genetic Testing

May 31st 2016

Mutations and the Risk for Breast Cancer

May 31st 2016

Value of Hereditary Breast Cancer Testing

May 31st 2016

Genetic Risk Assessment for Breast Cancer

May 31st 2016

Abemaciclib Active Against Multiple Tumor Types

May 30th 2016

Phase I trial results demonstrate that abemaciclib, a CDK 4/6 inhibitor, had significant clinical activity and an overall response rate of 31% in patients with hormone receptor-positive breast cancer.

Frontline Fulvestrant Bests Anastrozole in Advanced Breast Cancer

May 28th 2016

Frontline treatment with fulvestrant improved progression-free survival versus anastrozole for postmenopausal patients with locally-advanced or metastatic HR-positive breast cancer.

Role of Radiation Therapy Evolves for Elderly Patients With Breast Cancer

May 23rd 2016

Kevin Hughes, MD, discusses the pros and cons of radiation therapy in elderly patients with breast cancer, as well as luminal A patients, and the overall changing role of the treatment in the field.

Dr. Piccart on the MINDACT Study for Early-Stage Breast Cancer

May 19th 2016

Martine J. Piccart, MD, PhD, professor of Oncology, Université Libre de Bruxelles, director of Medicine, Jules Bordet Institute, Brussels, Belgium, discusses the primary analysis of the prospective randomized MINDACT study, which evaluated the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.